Answers are grounded in this paper and cite their sources.
Recent investigations have emphasized the therapeutic potential of thiazole derivatives in oncology. In this study, the novel compound 2-[(4,5-dihydrothiazol-2-yl)thio]-N-(4-methylthiazol-2-yl)acetamide was evaluated for its cytotoxic and mechanistic effects on PC-3 prostate cancer cells. Cell viability decreased significantly after treatment (∗∗∗∗p ≤ 0.0001), and HEK-293 cells showed relative resistance at lower doses. Annexin V/PI flow cytometry revealed a dose-dependent increase in apoptosis, most pronounced at 88 μM (∗∗∗∗p < 0.0001), and JC-1 assays confirmed membrane depolarization (∗∗∗∗p < 0.0001). RT-qPCR analysis revealed significant downregulation of PSA and c-MYC (∗∗∗∗p < 0.0001) with a mild increase in TP53 expression. ELISA-based protein quantification showed elevated Caspase-3 and a biphasic modulation of Cytochrome-c, supporting activation of intrinsic apoptosis. GPX4 levels remained largely unchanged except at 128 μM, and SEMA3A expression was not significantly affected. Among inflammatory cytokines, TNF-α levels increased dose-dependently (∗∗∗∗p < 0.0001), while IL-6 and IL-10 showed no significant alterations. Collectively, These findings indicate that the synthesized thiazole compound exerts selective cytotoxicity toward prostate cancer cells via mitochondria-mediated apoptosis and inflammatory signaling modulation.
No takes yet. Share an insight, caveat, or question.
Meriç et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: